Efficacy and safety of long-term bisphosphonates in postmenopausal osteoporosis

Bibliography

• RUSSELL RG, SMITH R, PRESTON C et al.: Diphosphonates in Paget's Disease. Lancet (1974) 1:894–896.
   PubMed Web of Science ®Google Scholar
• WATTS NB, HARRIS ST, GENANT HK et al.: Intermittent cyclical etidronate tratement of postmenopausal osteoporosis. New EngI.j Med. (1990) 323:73–79.
   PubMed Web of Science ®Google Scholar
• BLACK DM, CUMMINGS SR, KARPF DB et at Randomized trial of theeffect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet (1996) 348(1):535–541.
   Google Scholar
• HARRIS S, WATTS NB, GENANT HKet al.: Effects of risedronate on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA (1999) 282:1344–1352.
   Google Scholar
• CUMMINGS SR, BLACK DM, THOMPSON D et al.: Effect ofalendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. JAMA (1998) 280:2077–2082.
   PubMed Web of Science ®Google Scholar
• REGINSTERJ-Y, MINNE H, SORENSEN OH et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis.Osteoporos. hat. (2000) 11:83–91.
   PubMedGoogle Scholar
• MCCLUNG M, GEUSENS P,MILLER PD et al.: Effect of risedronateon the risk of hip fracture in the elderly. N Engl. J. Med. (2001) 344:333–340.
   Google Scholar
• MCCLUNG MR, CLEMMESEM B, DAIFOTIS A et al.: Alendronate prevents postmenopausal bone loss in women without osteoporosis. Ann. Intern. Med. (1998) 128:253–261.
   PubMed Web of Science ®Google Scholar
• FOGELMAN I, RIBOT C, SMITH R et al.: Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multi-national, double-blind, placebo-controlled trial." Clin. Endocrinol. Metal,. (2002) 85:1895–1900.
   Google Scholar
• ROSSOUW JE, ANDERSON GL, PRENTICE RL et al.: Writing group for the women's health initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. "AMA (2002) 288:321–333.
   Google Scholar
• SHUMAKER SA, LEGAULT C, THAL L et al.: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study; a randomized controlled trial. JAMA (2003) 289:2651–2662.
   PubMed Web of Science ®Google Scholar
• SIRIS E, MILLER PD, BARRETT-CONNER E et al.: Identification and fracture outcomes of undiagnosed low bone density in postmenopausal women: results from The National Osteoporosis Risk Assessment (NORA). JAMA (2001) 286:2815–2822.
   PubMed Web of Science ®Google Scholar
• BARRETT-CONNOR E, WEHREN LE, SIRIS ES et al. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. Menopause (2003) 10(5):412–419.
   PubMed Web of Science ®Google Scholar
• SORENSEN OH, CRAWFORD GM, MULDER H et al.: (2003) Long-term effect of risedronate: a 5 year placebo-controlled clinical experience.Bone 32:120–126.
   Google Scholar
• TONINO RP, MEUNIER PJ, EMKEY R et al.: Skeletal effects of alendronate: 7 year treatment of postmenpausal women. Phase III." Cilia. Endocrinol. Metal,. (2000) 85:3109–3115.
   Google Scholar
• EMKEY R, REID I, MULLOY A et al.: Ten-year efficacy and safety of alendronate in the treatment of osteoporosis inpostmenopausal women. J. Bone Miner. Res. (2002) 17\(Suppl. 1):5139.
   Google Scholar
• SORENSON OH, KAUFMAN JM, WENDEROTH D et al.: Sustained effect of risedronate: a 7-year study in postmenopausal women." Clin. Densit. (2003) 6(2):191.
   Google Scholar
• WASNICH RD AND MILLER PD: Antifracture efficacy of antiresorptive agents are related to changes in bone density. .1. Clin. Endocrinol. Metal,. (2001) 85:231–236.
   Google Scholar
• CUMMINGS SR, KARPF DB, HARRIS F,GENANT HK, ENSRUD K,LACROIX AZ, BLACK D: Improvements in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am. J. Med. (2002) 114:281–289.
   Google Scholar
• HOCHBURG MC, GREENSPAN S, WASNICH RD, MILLER PD, THOMPSON DE, ROSS PD: Changes in bone density and turnover explain the reductions in incidence of non-vertebral fractures that occur during treatment with antiresorptive agents. J. Clin. Endocrinol. Metal,. (2002) 87:1586–1592.
   PubMedGoogle Scholar
• RODAN GA: Mechanisms of action of bisphosphonates Ann. Rev. Phammacol. Toxicol. (1998) 38:375–388.
   PubMed Web of Science ®Google Scholar
• RUSSELL RG AND ROGERS MJ: Bisphosphonates: from the laboaratory to the clinic and back again. Bone (1999) 25:97–106.
   PubMedGoogle Scholar
• VITTE C, SLEISCH H,GUENTHER HL: Bisphosphonates induce osteoblasts to secrete and inhibitor of osteoclast-mediated bone resorption. Endocrinology (1996) 137:324–333.
   Google Scholar
• WEINSTEIN RS, MANOLAGAS S: Apoptosis and osteoporosis. Am. .1. Med. (2000) 108(2):153–164.
   Google Scholar
• MASHIBA T, TURNER CH, HORANO T et al.: Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles Bone (2001) 28:524–531.
   Google Scholar
• LI J, MASHIBA T, BURR DB: Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Cakil Tissue Int. (2001) 69(5):281–286.
   PubMedGoogle Scholar
• CHAVASSIEUX PM, ARLOT ME, REDA C et al.: Histomorphometric assessment of the long-term effects of alendronate on bone quality andremodeling in patients with osteoporosis. J. Clin. Invest. (1997) 100:1475–1480.
   PubMed Web of Science ®Google Scholar
• ERIKSEN E, MELSEN S, SOD E et al: Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone (2002) 31(5):620–625.
   PubMed Web of Science ®Google Scholar
• DING M, DAY JS, BURR DB et al.: Canine cancellous bone microarchitecture after one year of high-dose bisphosphonates. Cakif Tissue Int. (2003) 72:737–744.
   PubMed Web of Science ®Google Scholar
• MILLER PD: Analsysis of 1-year vertebral fracture risk reduction data in treatments for osteoporosis. Southern Med. Assoc. 1 (2003) 96:478–485.
   PubMedGoogle Scholar
• COCO M, RUSH H: Increased incidence of hip fractures in dialysis patients with PTH levels in the adynamic range. Am. J. Kid. Dis. (2001) 36:1115–1121.
   Google Scholar
• WEINSTEIN RS: Perspective: true strength. j. Bone Miner. Res. (2000) 15:621–625.
   PubMed Web of Science ®Google Scholar
• MILLER PD, WATTS NB, LICATA AA et al.: Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after 7 years of treatment. Am..! Med. (1997) 103:468–478.
   PubMed Web of Science ®Google Scholar
• GREENSPAN S, EMKEY R,BONE HG 3rd et al: Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. Ann. Intern. Med. (2002) 137:875–883.
   PubMed Web of Science ®Google Scholar
• RAVN P, WEISS SR,RODRIGUEZ-PORTALES JA et al: Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawl. I Clin. Endocrinol. Metal,. (2000) 85:1492–1497.
   PubMed Web of Science ®Google Scholar
• MORTENSEN L, CHARLES P, BEKKER PJ et al.: Risedronate increases bone mass in an early postmenopausal population : two years of treatment plus one year of follow-up. J. Clin. Endocrinol. Metal,. (1998) 83:396–402.
   PubMed Web of Science ®Google Scholar
• NANCOLLAS G, TANG R, ROGERS MJ et al.: Mineral binding affinities of bisphosphonates." Bone Miner. Res. (2002) 17:368–372.
   Google Scholar
• KAHN SA, KANIS JA, VASIKARAN S et al.: Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis.' Bone Miner. Res. (1997) 12: 1700-1707.
   Google Scholar
• EASTELL R, BARTON I, HANNON RA et al.: Relationship of early changes in boneresorption to the reduction in fracture risk with risedronate. J. Bone Miner. Res. (2003) 18:1051–1056.
   PubMed Web of Science ®Google Scholar
• BORAH B, DUFRENSE TE, CHMIELEWSKI PA et al.: Risedronate preserves bone architecture in osteoporotic postmenopausal womenas measured by 3-DF micro-computed tomography. I Bone Miner. Res. (2002) 17:1139-1145.Affiliation
   Google Scholar